Sudan Loganathan
Stock Analyst at Stephens & Co.
(2.14)
# 2,948
Out of 5,017 analysts
36
Total ratings
44.83%
Success rate
-2.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.11 | +184.36% | 3 | Sep 22, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $16 → $14 | $9.80 | +42.86% | 2 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $26.77 | +68.10% | 3 | Sep 9, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $9.72 | +208.64% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $38.44 | +56.09% | 5 | Jun 24, 2025 | |
| DCTH Delcath Systems | Reiterates: Overweight | $25 | $11.35 | +120.26% | 3 | Jun 23, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $14.25 | +110.53% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $20.40 | +61.76% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $4.61 | +73.54% | 2 | Feb 24, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $8.12 | +84.73% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $60 | $59.89 | +0.18% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.61 | +210.56% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $3.45 | +276.81% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $11.79 | +748.18% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.47 | +709.72% | 1 | May 14, 2024 |
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.11
Upside: +184.36%
Arvinas
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $14
Current: $9.80
Upside: +42.86%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $26.77
Upside: +68.10%
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $9.72
Upside: +208.64%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $38.44
Upside: +56.09%
Delcath Systems
Jun 23, 2025
Reiterates: Overweight
Price Target: $25
Current: $11.35
Upside: +120.26%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $14.25
Upside: +110.53%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $20.40
Upside: +61.76%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $4.61
Upside: +73.54%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $8.12
Upside: +84.73%
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $59.89
Upside: +0.18%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.61
Upside: +210.56%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $3.45
Upside: +276.81%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $11.79
Upside: +748.18%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.47
Upside: +709.72%